FI110307B - Estrogeeni/progestiini/antiprogestiinia sisältävä ehkäisyvalmiste ja pakkaus - Google Patents
Estrogeeni/progestiini/antiprogestiinia sisältävä ehkäisyvalmiste ja pakkaus Download PDFInfo
- Publication number
- FI110307B FI110307B FI944022A FI944022A FI110307B FI 110307 B FI110307 B FI 110307B FI 944022 A FI944022 A FI 944022A FI 944022 A FI944022 A FI 944022A FI 110307 B FI110307 B FI 110307B
- Authority
- FI
- Finland
- Prior art keywords
- estrogen
- progestin
- antiprogestin
- days
- oral
- Prior art date
Links
- 239000000583 progesterone congener Substances 0.000 title claims description 71
- 239000000262 estrogen Substances 0.000 title claims description 68
- 229940011871 estrogen Drugs 0.000 title claims description 66
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims description 65
- 230000000708 anti-progestin effect Effects 0.000 title claims description 41
- 239000003418 antiprogestin Substances 0.000 title claims description 41
- 239000003433 contraceptive agent Substances 0.000 title claims description 24
- 230000002254 contraceptive effect Effects 0.000 title claims description 21
- 239000000203 mixture Substances 0.000 title description 5
- 238000009472 formulation Methods 0.000 title description 4
- 230000005906 menstruation Effects 0.000 claims description 30
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims description 28
- 230000002175 menstrual effect Effects 0.000 claims description 22
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 14
- 229960002568 ethinylestradiol Drugs 0.000 claims description 14
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 13
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 10
- 229930182833 estradiol Natural products 0.000 claims description 10
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 9
- 229960005309 estradiol Drugs 0.000 claims description 9
- 229960001652 norethindrone acetate Drugs 0.000 claims description 9
- 230000027758 ovulation cycle Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- 229960003248 mifepristone Drugs 0.000 claims description 5
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 claims description 4
- 229960005352 gestodene Drugs 0.000 claims description 4
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 4
- 229950011093 onapristone Drugs 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 3
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims description 3
- 229960001390 mestranol Drugs 0.000 claims description 3
- 229940035811 conjugated estrogen Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 description 32
- 208000034158 bleeding Diseases 0.000 description 32
- 230000000740 bleeding effect Effects 0.000 description 32
- 239000003826 tablet Substances 0.000 description 30
- 239000003539 oral contraceptive agent Substances 0.000 description 28
- 238000011282 treatment Methods 0.000 description 27
- 229940127234 oral contraceptive Drugs 0.000 description 26
- 229940079593 drug Drugs 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 239000006187 pill Substances 0.000 description 11
- 201000000736 Amenorrhea Diseases 0.000 description 9
- 206010001928 Amenorrhoea Diseases 0.000 description 9
- 231100000540 amenorrhea Toxicity 0.000 description 9
- 241000282693 Cercopithecidae Species 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 229960003387 progesterone Drugs 0.000 description 7
- 239000000186 progesterone Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000288906 Primates Species 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000002357 endometrial effect Effects 0.000 description 5
- 230000003325 follicular Effects 0.000 description 5
- 229960004400 levonorgestrel Drugs 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 206010046788 Uterine haemorrhage Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940124558 contraceptive agent Drugs 0.000 description 4
- 230000016087 ovulation Effects 0.000 description 4
- 239000000044 progesterone antagonist Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 206010057687 Bloody discharge Diseases 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- -1 dihydro-spirenone Chemical compound 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical class 0.000 description 2
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 231100000546 inhibition of ovulation Toxicity 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 229940044953 vaginal ring Drugs 0.000 description 2
- 239000006213 vaginal ring Substances 0.000 description 2
- INJBMNNLSBCVGV-QDWSJHPCSA-N (8r,9r,10s,13r)-13-methyl-2,4,5,6,7,8,9,10,11,12-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C([C@@H]12)CC(=O)CC1CC[C@@H]1[C@@H]2CC[C@@]2(C)C1=CC=C2 INJBMNNLSBCVGV-QDWSJHPCSA-N 0.000 description 1
- GEONECATAKDDLT-JDSZYESASA-N (8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol;[(8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 GEONECATAKDDLT-JDSZYESASA-N 0.000 description 1
- RCOWGILQXUPXEW-FUSOFXSQSA-N (8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-[(z)-3-hydroxyprop-1-enyl]-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@@]2(O)\C=C/CO)[C@]2(C)C1 RCOWGILQXUPXEW-FUSOFXSQSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002166 estriols Chemical class 0.000 description 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 229950001701 lilopristone Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 229960001207 micronized progesterone Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 229960000417 norgestimate Drugs 0.000 description 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
- 239000003217 oral combined contraceptive Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000018528 secretion by tissue Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84305892A | 1992-03-02 | 1992-03-02 | |
| US84305892 | 1992-03-02 | ||
| PCT/US1993/001931 WO1993017686A1 (en) | 1992-03-02 | 1993-03-02 | Estrogen/progestin/antiprogestin method and kit for oral contraception and regulating menses |
| US9301931 | 1993-03-02 | ||
| CN93102182 | 1993-03-02 | ||
| CN93102182A CN1090481C (zh) | 1992-03-02 | 1993-03-02 | 雌激素/孕激素/抗孕激素的应用,其组合物和药盒 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI944022L FI944022L (fi) | 1994-09-01 |
| FI944022A0 FI944022A0 (fi) | 1994-09-01 |
| FI110307B true FI110307B (fi) | 2002-12-31 |
Family
ID=25743002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI944022A FI110307B (fi) | 1992-03-02 | 1994-09-01 | Estrogeeni/progestiini/antiprogestiinia sisältävä ehkäisyvalmiste ja pakkaus |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7538099B1 (pl) |
| EP (1) | EP0630246B1 (pl) |
| JP (1) | JP4152431B2 (pl) |
| CN (1) | CN1090481C (pl) |
| AU (1) | AU678150B2 (pl) |
| BR (1) | BR9306005A (pl) |
| CZ (1) | CZ291988B6 (pl) |
| FI (1) | FI110307B (pl) |
| IL (1) | IL104915A (pl) |
| MX (1) | MX9301121A (pl) |
| NO (1) | NO311327B1 (pl) |
| NZ (1) | NZ268304A (pl) |
| PL (2) | PL172790B1 (pl) |
| SK (1) | SK285963B6 (pl) |
| WO (1) | WO1993017686A1 (pl) |
| ZA (1) | ZA931492B (pl) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9301121A (es) | 1992-03-02 | 1993-09-01 | Schering Ag | Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina. |
| US5468736A (en) * | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
| DE4335876A1 (de) * | 1993-10-17 | 1995-04-20 | Schering Ag | Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen |
| US5521166A (en) * | 1994-12-19 | 1996-05-28 | Ortho Pharmaceitical Corporation | Antiprogestin cyclophasic hormonal regimen |
| DE19531936A1 (de) * | 1995-08-17 | 1997-02-20 | Schering Ag | Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend |
| US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
| CN1281363A (zh) | 1997-11-14 | 2001-01-24 | 阿克佐诺贝尔公司 | 孕激素-抗孕激素体系 |
| US6020328A (en) * | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| US5962444A (en) * | 1998-05-29 | 1999-10-05 | Research Triangle Institute | 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| US6262042B1 (en) | 1998-05-29 | 2001-07-17 | Research Triangle Institute | 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| JP2002543136A (ja) * | 1999-04-29 | 2002-12-17 | アクゾ・ノベル・エヌ・ベー | 併用療法における抗プロゲスタゲンの使用 |
| RU2145848C1 (ru) * | 1999-07-19 | 2000-02-27 | Авакян Гагик Норайрович | Средство для лечения вторичной аменореи центрального генеза |
| IL148417A0 (en) | 1999-08-31 | 2002-09-12 | Jenapharm Gmbh | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) |
| EP2305230B1 (en) | 2001-12-05 | 2015-11-04 | Teva Women's Health, Inc. | Oral contraceptives to prevent pregnancy |
| CA2524474A1 (en) * | 2003-05-02 | 2004-11-18 | Duramed Pharmaceuticals, Inc. | Methods of hormonal treatment utilizing extended cycle contraceptive regimens |
| JP2007534622A (ja) * | 2003-07-16 | 2007-11-29 | デュラメド ファーマシューティカルズ インコーポレーティッド | 連続的エストロゲン投与での避妊薬療法を利用するホルモン処置の方法 |
| US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| TW200727920A (en) * | 2005-06-21 | 2007-08-01 | Organon Nv | New regimens for oral monophasic contraceptives |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9603856B2 (en) | 2013-11-03 | 2017-03-28 | Flamina Holding Ag | Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells |
| CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
| MX391191B (es) | 2014-11-17 | 2025-03-21 | Context Biopharma Inc | Composiciones de liberación extendida de onapristona y métodos. |
| EP3297634A1 (en) * | 2015-05-18 | 2018-03-28 | Agile Therapeutics, Inc. | Contraceptive compositions and methods for improved efficacy and modulation of side effects |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10308676B2 (en) | 2015-09-25 | 2019-06-04 | Context Biopharma Inc. | Methods of making onapristone intermediates |
| WO2017106214A1 (en) | 2015-12-15 | 2017-06-22 | Arno Therapeutics, Inc. | Amorphous onapristone compositions and methods of making the same |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2018102369A1 (en) | 2016-11-30 | 2018-06-07 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
| JP2023084729A (ja) * | 2021-12-08 | 2023-06-20 | 株式会社Ihc | 月経誘発キット |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3890356A (en) | 1973-03-26 | 1975-06-17 | Richardson Merrell Inc | 7-Alkyl-{66 {hu 3,5{b -steroids |
| US3928398A (en) | 1973-11-01 | 1975-12-23 | Richardson Merrell Inc | Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol |
| US4018919A (en) * | 1975-07-16 | 1977-04-19 | Eli Lilly And Company | Sequential contraceptive method using two types of progestational agents |
| US4416822A (en) | 1982-07-09 | 1983-11-22 | The Upjohn Company | 17β-Difluoromethyl steroids |
| IL68222A (en) | 1983-03-24 | 1987-02-27 | Yeda Res & Dev | Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity |
| US4780461A (en) | 1983-06-15 | 1988-10-25 | Schering Aktiengesellschaft | 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same |
| ES8502612A1 (es) * | 1983-06-15 | 1985-02-01 | Schering Ag | Procedimiento para la preparacion de 13a-alquilgonanos |
| AU572589B2 (en) | 1983-12-14 | 1988-05-12 | Upjohn Company, The | 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids |
| IE61236B1 (en) * | 1986-07-15 | 1994-10-19 | American Home Prod | Combination dosage form for pre-menopausal women |
| DE3702383A1 (de) | 1987-01-23 | 1988-08-04 | Schering Ag | 11ss-alkinylestrene und -estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| US5116818A (en) | 1987-03-10 | 1992-05-26 | Medical College Of Hampton Roads | Method and kit for contraception with GnRH-antagonist |
| US5108995A (en) | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
| MX9301121A (es) | 1992-03-02 | 1993-09-01 | Schering Ag | Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina. |
| US5439913A (en) | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
| US5622943A (en) | 1992-05-06 | 1997-04-22 | The Medical College Of Hampton Roads | Minimizing progestin associated breakthrough bleeding |
| WO1993021926A1 (en) | 1992-05-06 | 1993-11-11 | Medical College Of Hampton Roads | Minimizing progestin associated breakthrough bleeding |
| US5516769A (en) | 1993-02-19 | 1996-05-14 | The Medical College Of Hampton Roads | Method of inhibiting fertilization |
| US5468736A (en) | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
| DE4344463A1 (de) | 1993-12-22 | 1995-06-29 | Schering Ag | Kombinationsprodukt zur Kontrazeption |
-
1993
- 1993-03-01 MX MX9301121A patent/MX9301121A/es active IP Right Grant
- 1993-03-02 ZA ZA931492A patent/ZA931492B/xx unknown
- 1993-03-02 CN CN93102182A patent/CN1090481C/zh not_active Expired - Fee Related
- 1993-03-02 BR BR9306005A patent/BR9306005A/pt not_active Application Discontinuation
- 1993-03-02 NZ NZ268304A patent/NZ268304A/en not_active IP Right Cessation
- 1993-03-02 SK SK1046-94A patent/SK285963B6/sk unknown
- 1993-03-02 AU AU37879/93A patent/AU678150B2/en not_active Ceased
- 1993-03-02 PL PL93316357A patent/PL172790B1/pl not_active IP Right Cessation
- 1993-03-02 IL IL10491593A patent/IL104915A/en not_active IP Right Cessation
- 1993-03-02 PL PL93304807A patent/PL174785B1/pl not_active IP Right Cessation
- 1993-03-02 JP JP51586993A patent/JP4152431B2/ja not_active Expired - Fee Related
- 1993-03-02 WO PCT/US1993/001931 patent/WO1993017686A1/en not_active Ceased
- 1993-03-02 EP EP93907185A patent/EP0630246B1/en not_active Expired - Lifetime
-
1994
- 1994-09-01 FI FI944022A patent/FI110307B/fi active
- 1994-09-01 NO NO19943234A patent/NO311327B1/no unknown
- 1994-09-01 CZ CZ19942111A patent/CZ291988B6/cs not_active IP Right Cessation
-
1995
- 1995-06-05 US US08/462,703 patent/US7538099B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU678150B2 (en) | 1997-05-22 |
| AU3787993A (en) | 1993-10-05 |
| EP0630246A1 (en) | 1994-12-28 |
| CN1079386A (zh) | 1993-12-15 |
| CN1090481C (zh) | 2002-09-11 |
| BR9306005A (pt) | 1998-06-23 |
| IL104915A (en) | 1998-07-15 |
| WO1993017686A1 (en) | 1993-09-16 |
| NO311327B1 (no) | 2001-11-19 |
| FI944022L (fi) | 1994-09-01 |
| IL104915A0 (en) | 1993-07-08 |
| US7538099B1 (en) | 2009-05-26 |
| EP0630246A4 (en) | 2002-07-17 |
| FI944022A0 (fi) | 1994-09-01 |
| NZ268304A (en) | 1997-02-24 |
| JP4152431B2 (ja) | 2008-09-17 |
| MX9301121A (es) | 1993-09-01 |
| SK285963B6 (sk) | 2007-12-06 |
| NO943234L (no) | 1994-11-01 |
| CZ291988B6 (cs) | 2003-07-16 |
| PL172790B1 (pl) | 1997-11-28 |
| EP0630246B1 (en) | 2008-07-16 |
| JPH07509218A (ja) | 1995-10-12 |
| ZA931492B (en) | 1993-12-23 |
| CZ211194A3 (en) | 1995-12-13 |
| SK104694A3 (en) | 1996-01-10 |
| PL174785B1 (pl) | 1998-09-30 |
| NO943234D0 (no) | 1994-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI110307B (fi) | Estrogeeni/progestiini/antiprogestiinia sisältävä ehkäisyvalmiste ja pakkaus | |
| DK174724B1 (da) | Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet | |
| RU2169567C2 (ru) | Способ контрацепции женщин репродуктивного возраста, не достигших предменопаузы | |
| US5276022A (en) | Hormone preparation and method | |
| US5108995A (en) | Hormone preparation and method | |
| EP0559240B1 (en) | Contraceptive packages containing oestrogen and progestin | |
| US5256421A (en) | Hormone preparation and method | |
| US7704983B1 (en) | Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception | |
| JPH11508538A (ja) | ホルモン避妊用薬剤の複合調剤、キット及び避妊方法 | |
| JPH11511157A (ja) | 避妊用複合調剤、複合調剤を含有するキット及び複合調剤の使用方法 | |
| HUP0202515A2 (hu) | Mezoprogesztogének (progeszteron receptor modulátorok) alkalmazása női fogamzásgátló gyógyszer komponenseként | |
| RU2127112C1 (ru) | Эстроген (прогестин)антипрогестиновый способ пероральной контрацепции и регулирования менструации, фармацевтическая композиция и набор лекарственных средств | |
| EP0368373A1 (en) | Multi-phase contraceptive preparation | |
| EP1605924B1 (en) | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) | |
| CA2134961C (en) | Estrogen/progestin/antiprogestin method and kit for oral contraception and regulating menses | |
| HK1077743B (en) | Composition for contraception |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer of assignment of patent |
Owner name: EASTERN VIRGINIA MEDICAL SCHOOL Free format text: EASTERN VIRGINIA MEDICAL SCHOOL |